Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
TKMR's Cash to Debt is ranked higher than
88% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. TKMR: No Debt )
TKMR' s 10-Year Cash to Debt Range
Min: 178.64   Max: No Debt
Current: No Debt

Equity to Asset 0.76
TKMR's Equity to Asset is ranked higher than
80% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. TKMR: 0.76 )
TKMR' s 10-Year Equity to Asset Range
Min: 0.03   Max: 0.9
Current: 0.76

0.03
0.9
Interest Coverage No Debt
TKMR's Interest Coverage is ranked higher than
90% of the 576 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TKMR: No Debt )
TKMR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 11.30
M-Score: -99999999.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -136.89
TKMR's Operating margin (%) is ranked higher than
69% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. TKMR: -136.89 )
TKMR' s 10-Year Operating margin (%) Range
Min: -22383.33   Max: 16.57
Current: -136.89

-22383.33
16.57
Net-margin (%) -197.06
TKMR's Net-margin (%) is ranked higher than
67% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. TKMR: -197.06 )
TKMR' s 10-Year Net-margin (%) Range
Min: -19172.92   Max: 209.94
Current: -197.06

-19172.92
209.94
ROE (%) -45.12
TKMR's ROE (%) is ranked higher than
71% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. TKMR: -45.12 )
TKMR' s 10-Year ROE (%) Range
Min: -984.09   Max: 127.91
Current: -45.12

-984.09
127.91
ROA (%) -34.91
TKMR's ROA (%) is ranked higher than
71% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. TKMR: -34.91 )
TKMR' s 10-Year ROA (%) Range
Min: -58.63   Max: 146.65
Current: -34.91

-58.63
146.65
ROC (Joel Greenblatt) (%) -1652.40
TKMR's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. TKMR: -1652.40 )
TKMR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1691.29   Max: 249.49
Current: -1652.4

-1691.29
249.49
Revenue Growth (3Y)(%) -19.60
TKMR's Revenue Growth (3Y)(%) is ranked higher than
67% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. TKMR: -19.60 )
TKMR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -29.8   Max: 268.4
Current: -19.6

-29.8
268.4
EBITDA Growth (3Y)(%) -10.60
TKMR's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. TKMR: -10.60 )
TKMR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 40.6
Current: -10.6

0
40.6
EPS Growth (3Y)(%) -6.80
TKMR's EPS Growth (3Y)(%) is ranked higher than
77% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. TKMR: -6.80 )
TKMR' s 10-Year EPS Growth (3Y)(%) Range
Min: -50.4   Max: 30.8
Current: -6.8

-50.4
30.8
» TKMR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

TKMR Guru Trades in Q1 2014

Steven Cohen 46,283 sh (New)
Jim Simons 25,000 sh (New)
» More
Q2 2014

TKMR Guru Trades in Q2 2014

Jim Simons 150,200 sh (+500.8%)
» More
Q3 2014

TKMR Guru Trades in Q3 2014

Paul Tudor Jones 100,000 sh (New)
Jim Simons 22,900 sh (-84.75%)
» More
Q4 2014

TKMR Guru Trades in Q4 2014

Jim Simons 26,700 sh (+16.59%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TKMR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-06-30 Sold Out $4.28 - $5.05 $ 17.93278%0
Jean-Marie Eveillard 2013-03-31 New Buy$4.35 - $5.44 $ 17.93279%25000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 14.73
TKMR's Forward P/E is ranked higher than
98% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TKMR: 14.73 )
N/A
P/B 4.76
TKMR's P/B is ranked higher than
77% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. TKMR: 4.76 )
TKMR' s 10-Year P/B Range
Min: 0.32   Max: 262.5
Current: 4.76

0.32
262.5
P/S 22.23
TKMR's P/S is ranked higher than
76% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. TKMR: 22.23 )
TKMR' s 10-Year P/S Range
Min: 0.74   Max: 32.98
Current: 22.23

0.74
32.98
EV-to-EBIT -22.61
TKMR's EV-to-EBIT is ranked higher than
59% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TKMR: -22.61 )
TKMR' s 10-Year EV-to-EBIT Range
Min: -29.4   Max: 91.9
Current: -22.61

-29.4
91.9
Current Ratio 5.73
TKMR's Current Ratio is ranked higher than
78% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. TKMR: 5.73 )
TKMR' s 10-Year Current Ratio Range
Min: 0.98   Max: 7.2
Current: 5.73

0.98
7.2
Quick Ratio 5.73
TKMR's Quick Ratio is ranked higher than
79% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. TKMR: 5.73 )
TKMR' s 10-Year Quick Ratio Range
Min: 0.98   Max: 7.2
Current: 5.73

0.98
7.2
Days Sales Outstanding 42.74
TKMR's Days Sales Outstanding is ranked higher than
88% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. TKMR: 42.74 )
TKMR' s 10-Year Days Sales Outstanding Range
Min: 2.76   Max: 996.15
Current: 42.74

2.76
996.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.74
TKMR's Price/Net Cash is ranked higher than
89% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. TKMR: 5.74 )
TKMR' s 10-Year Price/Net Cash Range
Min: 0.71   Max: 38.5
Current: 5.74

0.71
38.5
Price/Net Current Asset Value 5.63
TKMR's Price/Net Current Asset Value is ranked higher than
88% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. TKMR: 5.63 )
TKMR' s 10-Year Price/Net Current Asset Value Range
Min: 0.7   Max: 209
Current: 5.63

0.7
209
Price/Tangible Book 4.76
TKMR's Price/Tangible Book is ranked higher than
82% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. TKMR: 4.76 )
TKMR' s 10-Year Price/Tangible Book Range
Min: 0.64   Max: 177.5
Current: 4.76

0.64
177.5
Price/DCF (Projected) 7.34
TKMR's Price/DCF (Projected) is ranked higher than
93% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TKMR: 7.34 )
TKMR' s 10-Year Price/DCF (Projected) Range
Min: 3.8   Max: 34.24
Current: 7.34

3.8
34.24
Price/Median PS Value 6.41
TKMR's Price/Median PS Value is ranked higher than
68% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. TKMR: 6.41 )
TKMR' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 6.78
Current: 6.41

0.28
6.78
Earnings Yield (Greenblatt) -4.40
TKMR's Earnings Yield (Greenblatt) is ranked higher than
71% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. TKMR: -4.40 )
TKMR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 99478.9
Current: -4.4

1.1
99478.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TKM.Canada, I9DN.Germany,
Tekmira Pharmaceuticals Corp was incorporated on October 6, 2005. The Company develops ribonucleic acid interference therapeutic product candidates as well as provides its lipid nanoparticle delivery technology to pharmaceutical partners in the Canada. The Company's internal product development candidates include TKM-PLK1, an oncology product candidate that is in Phase I clinical trials to kill cancer cells; and TKM-Ebola, an antiviral product, which is in Phase I of clinical trials for the treatment of the Zaire species of Ebola virus infection. In addition, the Company has licenses from Alnylam targeting two validated oncology targets, WEE1 and CSN5; and to develop TKM-ALDH2, a systemically delivered RNAi therapeutic that utilizes lipid nanoparticle technology for the treatment of alcohol dependence.
» More Articles for TKMR

Headlines

Articles On GuruFocus.com
Tekmira Pharmaceuticals Gets Mixed Ratings After Ebola Drug Updates Nov 11 2014 
Ebola: Is The Cure Out There? Oct 14 2014 
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 

More From Other Websites
Nasdaq stocks posting largest percentage increases Mar 02 2015
ZMapp Ebola Trial Starts In Liberia: Is It Too Late? Mar 01 2015
Tekmira Announces Update to Its Proxy Circular on the Proposed Business Combination With OnCore... Feb 25 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 12 2015
Tekmira to Present at RBC Capital Markets' Healthcare Conference Feb 12 2015
Tekmira to Present at RBC Capital Markets' Healthcare Conference Feb 12 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 11 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Changes in Control or Registrant, Other Events,... Feb 05 2015
Tekmira Announces Filing of Definitive Proxy Statement and Voluntary Delisting From the TSX Feb 04 2015
Tekmira Announces Filing of Definitive Proxy Statement and Voluntary Delisting From the TSX Feb 04 2015
The 3 Best Biotech Stocks Of The Last 30 Days Feb 02 2015
Tekmira Pharmaceuticals, Lakeland Industries Moving On Possible Ebola Case In California Jan 29 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 28 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K/A, Entry into a Material Definitive Agreement,... Jan 26 2015
Tekmira Pharmaceuticals Corporation (TKMR): Falcon Edge Capital Discloses 10% Passive Stake Jan 26 2015
5 stocks to watch Jan 22 2015
Tekmira Initiates Phase I Clinical Trial of TKM-HBV Jan 21 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 21 2015
Tekmira Initiates Phase I Clinical Trial of TKM-HBV Jan 21 2015
Vical Up on Deal with AnGes to Develop Ebola Treatment - Analyst Blog Jan 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK